Pharmaceutical firms' patent strategies deter competition, says EU inquiry report
This article was originally published in Scrip
Executive Summary
"Originator companies have designed and implemented patent strategies aimed at hindering their competitors and thereby ensuring continued revenue streams for their medicines," Neelie Kroes, the EU's competition commissioner, told a conference in Brussels this morning on the inquiry into competition in the pharmaceutical sector.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.